The demand for ventilators underwent a significant surge due to the onset of the COVID-19 pandemic. The global health crisis put a spotlight on the importance of ventilators and the critical role they play in saving lives. As a result, the ventilator market saw a rapid increase in demand, forcing companies to quickly restructure their strategies to keep up with the changing market. In the aftermath of the pandemic, companies are now reassessing their position in the market and exploring new ways to maintain their competitiveness. In this blog, we will discuss some interesting insights in the neonatal ventilator market and how some companies are adapting to the changing landscape.
Acutronic and Bunnell: A Tale of Two Ventilators in the Evolving Market
The neonatal ventilator market has seen some interesting changes over the past few years. Two players in the space, Acutronic and Bunnell, have experienced fluctuations in their overall revenue generated. When looking at the data from Q2 2020 compared to Q2 2022, we can see that Acutronic’s Monsoon III saw a drastic decline in revenue. On the other hand, Bunnell’s Life Pulse also experienced a decrease, but not to the same extent as Acutronic. Both Monsoon III and Life Pulse are high-frequency jet ventilators (HFJV) and are known for their gentle approach and ability to oxygenate at lower mean airway pressures.
It’s no secret that during the COVID-19 pandemic, the demand for ventilators skyrocketed. This surge in demand was reflected in the increased popularity of Acutronic’s Monsoon III. However, as the pandemic began to subside, the demand for ventilators dropped and Monsoon III’s revenue returned to pre-pandemic levels and below. One interesting factor to note is that Acutronic positions Monsoon III at a slightly higher average selling price (ASP) compared to Bunnell’s Life Pulse offering. This may have contributed to the larger decrease in revenue generated by Monsoon III.
Percussionaire’s Bold Move: Increasing ASPs
On the other side of the spectrum, Percussionaire made a bold move by increasing the average selling price (ASP) of its VDR-4 neonatal ventilator by ~$3,000 and the results paid off. The company saw approximately an impressive 127% increase in overall revenue generated in Q2 2022, compared to Q1 2021. The VDR-4 neonatal ventilator, designed for hospital use, is a flow-regulated, time-cycled device that provides high-frequency percussive ventilation (HFPV). With its versatility and many features and benefits, the VDR-4 has been able to quickly bounce back from the inflation caused by COVID-19 in 2020 and early 2021 and maintain an upward trajectory.
While the overall revenue generated from the VDR-4 has yet to surpass that of Bunnell’s Life Pulse, the long-term trajectory of this device looks promising. The company’s decision to increase the ASP and focus on the benefits of the VDR-4 has paid off and continues to drive success.
MEDSKU: FURTHER INSIGHTS
In conclusion, the neonatal ventilator market is constantly changing and it will be fascinating to see how these shifts impact the players involved. With detailed brand and SKU-level intelligence, you can gain a comprehensive view of your competitors’ strategies, uncover untapped opportunities, and make data-driven decisions. Our dedicated team has been working tirelessly to analyze the latest data and trends in the US Ventilator Market, ensuring our clients remain at the forefront of the industry. If you’re interested in learning more about the above insights, request a MedSKU demo through the link below to see our platform in action.
